Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Cited In for PubMed (Select 15273746)

1.

SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.

Zhou Y, Mohan A, Moore DC, Lin L, Zhou FL, Cao J, Wu Q, Qin YX, Reginato AM, Ehrlich MG, Yang W.

FASEB J. 2015 May;29(5):1635-45. doi: 10.1096/fj.14-260844. Epub 2015 Jan 15.

PMID:
25593124
2.

RAS diseases in children.

Niemeyer CM.

Haematologica. 2014 Nov;99(11):1653-62. doi: 10.3324/haematol.2014.114595.

3.

The Q510E mutation in Shp2 perturbs heart valve development by increasing cell migration.

Edwards MA, Crombie K, Schramm C, Krenz M.

J Appl Physiol (1985). 2015 Jan 1;118(1):124-31. doi: 10.1152/japplphysiol.00008.2014. Epub 2014 Oct 30.

PMID:
25359717
4.

K-RasV14I recapitulates Noonan syndrome in mice.

Hernández-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Cañamero M, Cámara JA, Cussó L, Desco M, Heeschen C, Mulero F, Bustelo XR, Guerra C, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16395-400. doi: 10.1073/pnas.1418126111. Epub 2014 Oct 30.

5.

Protein tyrosine phosphatases as potential therapeutic targets.

He RJ, Yu ZH, Zhang RY, Zhang ZY.

Acta Pharmacol Sin. 2014 Oct;35(10):1227-46. doi: 10.1038/aps.2014.80. Epub 2014 Sep 15. Review.

6.

Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Zhang RY, Walls CD, Chen L, Zhang S, Wu L, Liu S, Zhang ZY.

Biochemistry. 2014 Jul 1;53(25):4136-51. doi: 10.1021/bi5002695. Epub 2014 Jun 17.

7.

A PTPN11 allele encoding a catalytically impaired SHP2 protein in a patient with a Noonan syndrome phenotype.

Edwards JJ, Martinelli S, Pannone L, Lo IF, Shi L, Edelmann L, Tartaglia M, Luk HM, Gelb BD.

Am J Med Genet A. 2014 Sep;164A(9):2351-5. doi: 10.1002/ajmg.a.36620. Epub 2014 May 28.

PMID:
24891296
8.

PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice.

Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, Stokes MP, Hui L, Silva JC, Overvoorde J, Giansanti P, Heck AJ, Kontaridis MI, den Hertog J, Bennett AM.

Mol Cell Biol. 2014 Aug;34(15):2874-89. doi: 10.1128/MCB.00135-14. Epub 2014 May 27.

9.

Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML.

Stirewalt DL, Pogosova-Agadjanyan EL, Tsuchiya K, Joaquin J, Meshinchi S.

Blood Cancer J. 2014 May 2;4:e208. doi: 10.1038/bcj.2014.27.

10.

Distinct and overlapping functions of ptpn11 genes in Zebrafish development.

Bonetti M, Rodriguez-Martinez V, Paardekooper Overman J, Overvoorde J, van Eekelen M, Jopling C, Hertog Jd.

PLoS One. 2014 Apr 15;9(4):e94884. doi: 10.1371/journal.pone.0094884. eCollection 2014.

11.

Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction.

Ulm S, Liu W, Zi M, Tsui H, Chowdhury SK, Endo S, Satoh Y, Prehar S, Wang R, Cartwright EJ, Wang X.

J Mol Cell Cardiol. 2014 Jul;72:104-16. doi: 10.1016/j.yjmcc.2014.03.002. Epub 2014 Mar 12.

12.

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).

Qiu W, Wang X, Romanov V, Hutchinson A, Lin A, Ruzanov M, Battaile KP, Pai EF, Neel BG, Chirgadze NY.

BMC Struct Biol. 2014 Mar 14;14:10. doi: 10.1186/1472-6807-14-10.

13.

The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon.

Ehrman LA, Nardini D, Ehrman S, Rizvi TA, Gulick J, Krenz M, Dasgupta B, Robbins J, Ratner N, Nakafuku M, Waclaw RR.

J Neurosci. 2014 Mar 5;34(10):3767-78. doi: 10.1523/JNEUROSCI.3515-13.2014.

14.

Genetic dissection of quantitative trait Loci for hemostasis and thrombosis on mouse chromosomes 11 and 5 using congenic and subcongenic strains.

Hoover-Plow J, Sa Q, Huang M, Grondolsky J.

PLoS One. 2013 Oct 17;8(10):e77539. doi: 10.1371/journal.pone.0077539. eCollection 2013.

15.

Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice.

Lapinski PE, Meyer MF, Feng GS, Kamiya N, King PD.

Dis Model Mech. 2013 Nov;6(6):1448-58. doi: 10.1242/dmm.012849. Epub 2013 Sep 25.

16.

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).

Liu W, Yu B, Xu G, Xu WR, Loh ML, Tang LD, Qu CK.

J Med Chem. 2013 Sep 26;56(18):7212-21. doi: 10.1021/jm400474r. Epub 2013 Sep 4.

17.
18.

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, Mackerell AD Jr, Tang LD, Qu CK.

Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.

19.
20.

Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Yu ZH, Xu J, Walls CD, Chen L, Zhang S, Zhang R, Wu L, Wang L, Liu S, Zhang ZY.

J Biol Chem. 2013 Apr 12;288(15):10472-82. doi: 10.1074/jbc.M113.450023. Epub 2013 Mar 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk